Eisai (TYO:4523) and Biogen plan to begin producing active ingredients for their Alzheimer's drug lecanemab in the US, shifting part of the work from Switzerland, Nikkei Asia Review reported Thursday.
The move came amid concern that US President Donald Trump would impose tariffs on pharmaceutical imports, the report said.
Biogen, which manufactures the drug, is preparing to build an ingredient production line at the North Carolina site, with the aim to begin domestic production within one to two years, the report said.
Eisai described the decision as part of its cost-cutting efforts but acknowledged the change would also help hedge against potential US tariffs, Nikkei reported.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。